Bessemer Group Inc. Has $218.31 Million Stake in Thermo Fisher Scientific Inc. $TMO

Bessemer Group Inc. trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.9% in the second quarter, HoldingsChannel.com reports. The firm owned 538,431 shares of the medical research company’s stock after selling 87,183 shares during the period. Bessemer Group Inc.’s holdings in Thermo Fisher Scientific were worth $218,313,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. CBIZ Investment Advisory Services LLC raised its stake in shares of Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 33 shares in the last quarter. Anderson Financial Strategies LLC acquired a new position in shares of Thermo Fisher Scientific in the first quarter valued at $30,000. Keystone Global Partners LLC acquired a new position in shares of Thermo Fisher Scientific in the first quarter valued at $31,000. DiNuzzo Private Wealth Inc. raised its stake in shares of Thermo Fisher Scientific by 406.7% in the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 61 shares in the last quarter. Finally, HighMark Wealth Management LLC raised its stake in shares of Thermo Fisher Scientific by 140.6% in the second quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 45 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TMO has been the subject of several recent analyst reports. Cowen reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday. Barclays increased their price objective on Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday. HSBC reiterated a “hold” rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price objective on Thermo Fisher Scientific and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. Finally, Robert W. Baird increased their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a research note on Thursday, July 24th. Nineteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $595.75.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares in the company, valued at $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,666 shares of company stock worth $13,990,971. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $573.07 on Monday. The stock’s fifty day moving average is $504.04 and its 200-day moving average is $453.56. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. The stock has a market capitalization of $216.40 billion, a PE ratio of 33.11, a PEG ratio of 3.35 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping the consensus estimate of $5.50 by $0.29. The company had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.